766PDLONG-TERM EFFICACY AND SAFETY OF ENZALUTAMIDE MONOTHERAPY IN HORMONE-NAIVE PROSTATE CANCER: 2-YEAR FOLLOW-UP

B. Tombal1, M. Borre2, P. Rathenborg3, P. Werbrouck4, H. van Poppel5, A. Heidenreich6, P. Iversen7, J. Braeckman8, J. Heracek9, E. Baskin-Bey10, T. Ouatas11, F.G. Perabo12, D. Phung13, B. Baron10, M. Hirmand14, M.R. Smith15 Urology, Cliniques Universitaires St. Luc, Brussels, BELGIUM Medicine, Aarhus University Hospital, Aarhus, DENMARK Urology, Herlev Hospital, Herlev, DENMARK Urology, AZ Groeninge Kortrijk, Kortrijk, BELGIUM Department of Urology, University Hospital Gasthuisberg, Leuven, BELGIUM Urology, RWTH Aachen University, Aachen, GERMANY Urology, Rigshospitalet, Copenhague, DENMARK Urology, UZ Brussels, Brussels, BELGIUM Urology, Univerzita Karlova v Praze, Prague, CZECH REPUBLIC Global Development, Astellas Pharma, Leidendorp, NETHERLANDS Explocatory Development, Astellas Pharma, Leiderdorp, NETHERLANDS Medical Science, Astellas Pharma Global Development, Deerfield, IL, USA Global Development, Astellas Pharma, Northbrook, IL, USA Clinical Development, Medivation, San Francisco, CA, USA Hematology-oncology, Massachusetts General Hospital, Boston, MA, USA